Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

Figure 5

Sensitivity analysis of (a) overall survival (OS), (b) progression-free survival (PFS), and (c) disease control rate (DCR).

(a)

(b)

(c)